• The new supplement is designed to enhance cell growth in manufacturing applications, especially within regenerative medicine and cell therapies.
  • Human Platelet Lysate (HPL) is presented as a safer and more sustainable substitute for Fetal Bovine/Calf Serum (FBS/FCS).
  • ELAREM™ Ultimate-FD PLUS, a gamma-irradiated product of GMP grade, is manufactured in Germany through a patented, exclusive process.

AACHEN, Germany, April 30, 2025 — PL BioScience GmbH, a German company focused on Human Platelet Lysate (HPL) production and development for cell expansion, has launched ELAREM™ Ultimate-FD PLUS. It is the only gamma-irradiated, GMP-grade Human Platelet Lysate produced in Germany using a globally patented process. Addressing the increasing need for safe, xeno-free, and ethically sourced cell culture supplements for cell therapy, regenerative medicine, and biopharmaceutical manufacturing, ELAREM™ Ultimate-FD PLUS provides a virus-inactivated, animal-free, and EU-manufactured option that adheres to the highest quality standards.

“We are excited to introduce the only gamma-irradiated Human Platelet Lysate made in Europe to the cell and gene therapy field,” stated Dr. Hatim Hemeda, CEO of PL BioScience. “This product is not just a European achievement, but a unique global offering. With complete patent protection and entirely EU-based production, ELAREM™ Ultimate-FD PLUS guarantees a stable supply chain, offering global manufacturers a high-quality, regulatory-compliant solution meeting top international standards.”

Cell culture supplements are vital for laboratory cell growth, crucial in developing and manufacturing advanced therapies like cell and gene therapies. Traditionally, these supplements often include components from other species, such as fetal bovine serum (FBS). These animal-derived products pose potential safety risks, like bacterial or viral contamination, and raise ethical concerns. HPL provides a fully human-derived, xeno-free alternative that is safe, consistent, and sustainable.

ELAREM™ Ultimate-FD PLUS advances this further. Through a proprietary gamma-irradiation process, the product undergoes viral inactivation, adding an extra layer of safety and regulatory assurance. The gamma-irradiated, xeno-free, fibrinogen-depleted, and anticoagulant-free product adheres to GMP (Good Manufacturing Practice) guidelines, making it suitable for cell manufacturing applications where viral reduction is critical, such as potential clinical trials.

About Human Platelet Lysate:

Human Platelet Lysate (HPL) is an innovative, human-derived cell culture supplement that supports cell growth and expansion in research and clinical development, particularly in cell therapy, stem cell, and regenerative medicine applications. It is produced from donated human blood platelets, unsuitable for transfusion and otherwise discarded, making it a sustainable and resource-efficient alternative to traditional cell culture supplements.

In cell culture, HPL offers key growth factors and nutrients that promote healthy, robust cell proliferation. Compared to conventional products like Fetal Bovine Serum (FBS), harvested from unborn calves, HPL delivers more consistent cell growth results, is free from animal-derived pathogens, and aligns with the growing demand for animal-free and ethically responsible laboratory practices.

ELAREM™, PL BioScience’s line of xeno-free HPL products, can be used from early-stage research to the production of cell-based therapies under Good Manufacturing Practice (GMP) conditions for patient treatment.

About PL BioScience:

Located in Aachen, Germany, PL BioScience GmbH specializes in producing and developing Human Platelet Lysate (HPL), offering a complete portfolio of HPL products for various use cases. From academic and preclinical research to cell therapy and biopharmaceutical manufacturing, ELAREM™ ensures seamless translation of regenerative medicine breakthroughs from the lab to patients. PL BioScience produces the only globally patented gamma-irradiated HPL product with ELAREM™ Ultimate-FD PLUS. For more on PL BioScience and the ELAREM™ product offerings, visit:

Contact:
Dr. Hatim Hemeda, CEO
PL BioScience GmbH
+49(0)24195719-100

Media contact:
MC Services AG
Raimund Gabriel, Dr. Regina Lutz
+49 (0)89 210 228 0
US: Catherine Featherston
+1-203-444-4393
E-Mail: